28 research outputs found
Differences in the chromosomal profile of AML-M0 versus AML-M1: response [letter; comment] [see comments]
Differences in the chromosomal profile of AML-M0 versus AML-M1: response.
In our study published in Blood in 1995, 26 patients with minimally
differentiated acute myeloid leukemia (AML-MO) were shown
to have a different cytogenetic profile with respect to 42 patients
with AML-M1. The observed high incidence of complex karyotypes
and of unfavorable chromosome changes such as -5/5q-, -7/7q-,
and + 13 in AML-MO may provide a biologic argument partially
explaining the poor prognosis of this newly recognized entity of
leukemia.’ The study by Venditti et a12 in the January l, 1996 issue
of Blood confirms that AML-MO has an unfavorable prognosis.
However, these investigators describe similar cytogenetic features
in AML-MO and AML-MI, which is at variance with our results.
We wish to analyze three possible factors, concerning (1) patient
selection, (2) influence of environmental exposure to myelotoxic
agents, and (3) statistical analysis, that may account for the discrepant
cytogenetic findings in these studies.
Twenty-six patients were selected in our analysis from approximately
700 newly diagnosed patients seen in Ferrara, Italy and in 4
Belgian Institutions. Fifteen additional patients with presumptive
diagnosis of AML-MO were excluded at centralized cytoimmunologic
review.’ Thus, the incidence of AML-MO in our multicenter
study is 3.7%. There is a very high incidence of AML-MO and AMLM1
in the study by Venditti et a l z (8.9% and 19.5%, respectively, in
256 AMLs), as compared with previous studies. The incidence of
AML-MO in 2 large series, totalling over 1,300 AML cases, ranged
between 0.1% and 4%3.4; likewise, a 16.4% and 10% incidence of
AML-M1 was recorded in the large GIMEMAEORTC trial and in
the GIMEMA study of 355 AML patients submitted to centralized
cytologic The patients of Venditti et alz with AML-M1
also have a higher incidence of chromosome changes (75%) than
was previously reported in 97 cases of de novo AML-MI studied
at the Fourth International Workshop on Chromosomes in Leukemia
(40.2%): It is worth noting that comparative analyses of original
French-American-British (FAB) diagnoses and reviewers’ diagnoses
in the GIMEMAEORTC group showed that the most frequent disagreement
(30% of total) was confined to those cases classified as
AML-M1 by refemng centers and recognized either as AML-M2
or AML with monocytic features at centralized review.’,’ The incidence
of chromosome changes varies according to the FAB type
and, therefore, homogeneous application of the FAB scheme is of
critical importance for studies comparing cytogenetic and cytologic
features.
Exposure to myelotoxic agents may also influence the rate of
chromosome abnormalities in leukemia. For instance, professional
exposure to organic solvents, petroleum products, or pesticides was
recorded frequently in our cases with complex karyotypes and with
+13.
In the study by Venditti et a1: data from only 28 of 50 observed
AML-M1 are used for cytogenetic comparison with AML-MO and
criteria for patient selection are not mentioned. The number of observed
cases in the different cytogenetic groups (-51-7, f13, +8,
+4, others, and normal) do not add up to the total number of patients
studied. The difference of patient distribution in three cytogenetic
categories (complex karyotype, abnormal with 1 or 2 changes, and
normal karyotype) in AML-MO versus AML-M1 approaches statistical
significance (P = .09). We agree with Venditti et alz that reagents
detecting myeloperoxidase are useful in the immunologic recognition
of AML-MO; however, the importance and the exact role of
this and other markers (CD1 17 and antilysozyme) in the diagnosis
of acute leukemia is currently being tested in a prospective European
stud
Targeting H3.3 mutated pediatric high grade gliomas – A high throughput screening approach to identify novel therapeutic agents
The Association of QT Dispersion and QT Dispersion Ratio with Extent and Severity of Coronary Artery Disease
Pigmented villonodular synovitis of the thoracic spine: case report and review of the literature Sinovitis vellonodular pigmentada de la columna torácica: informe de un caso y revisión de la literatura Sinovitis pigmentada vilonodular da coluna torácica: relato de caso e revisão da literatura
Pigmented Villonodular Synovitis (PVNS), a lesion of the synovial tissues, is rarely found in the spine. We present a 73-year-old male with increasing lower extremity weakness and paresthesias. MRI scans revealed disc herniation and spinal cord compression at the T11-T12 and T12- L1 levels. Intraoperative exploration revealed an epidural mass originating in the T12 lamina, compressing the spinal cord at T11-T12. Pathologic examination was consistent with pigmented villonodular synovitis.<br>Sinovitis vellonodular pigmentada (PVNS) es una lesión del tejido sinovial y raramente se encuentra en la columna vertebral. Presentamos el caso de un hombre de 73 años de edad que mostró aumento de la flaqueza de la extremidad inferior y parestesias. El examen de imagen por resonancia magnética indicó una hernia de disco y compresión en el nivel de T11-T12 y T12-L1. La exploración quirúrgica evidenció una masa epidural originaria en T2 y compresión de la médula espinal a nivel de T11-T12. El examen patológico fue compatible con sinovitis vellonodular pigmentada.<br>Sinovitis pigmentada vilonodular (PVNS) é uma lesão do tecido sinovial e raramente é encontrada na coluna vertebral. Apresentamos o caso de um homem de 73 anos de idade com aumento de fraqueza da extremidade inferior e parestesia. O exame de imagem por ressonância magnética revelou hérnia de disco e compressão no nível T11-T12 e T12-L1. A exploração cirúrgica evidenciou massa epidural orginária em T2 e compressão da medula espinhal no nível de T11-T12. O exame patológico foi compatível com sinovitis pigmentada vilonodular
